Lipocine Inc. (NASDAQ:LPCN) has been assigned a $38.00 price objective by research analysts at Roth Capital in a research note issued on Thursday. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock.

Other research analysts have also issued research reports about the company. Canaccord Genuity set a $11.00 price target on Lipocine and gave the stock a “buy” rating in a research note on Monday. HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of Lipocine in a research note on Wednesday, April 26th. Finally, ValuEngine lowered Lipocine from a “hold” rating to a “sell” rating in a research report on Thursday.

Shares of Lipocine (LPCN) traded down 3.70% during trading on Thursday, reaching $4.16. The company had a trading volume of 205,831 shares. The firm’s 50 day moving average price is $4.45 and its 200 day moving average price is $3.99. The firm’s market capitalization is $85.62 million. Lipocine has a 12 month low of $3.03 and a 12 month high of $5.90.

Lipocine (NASDAQ:LPCN) last announced its earnings results on Monday, August 7th. The specialty pharmaceutical company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by $0.01. Equities analysts predict that Lipocine will post ($1.15) EPS for the current year.

WARNING: “Lipocine Inc. (NASDAQ:LPCN) Given a $38.00 Price Target by Roth Capital Analysts” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/10/lipocine-inc-nasdaqlpcn-given-a-38-00-price-target-by-roth-capital-analysts.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. KCG Holdings Inc. increased its stake in shares of Lipocine by 27.4% in the first quarter. KCG Holdings Inc. now owns 33,537 shares of the specialty pharmaceutical company’s stock valued at $131,000 after buying an additional 7,219 shares in the last quarter. LMR Partners LLP acquired a new stake in shares of Lipocine during the second quarter valued at $173,000. Parametric Portfolio Associates LLC increased its stake in shares of Lipocine by 27.1% in the first quarter. Parametric Portfolio Associates LLC now owns 58,739 shares of the specialty pharmaceutical company’s stock valued at $229,000 after buying an additional 12,518 shares in the last quarter. Federated Investors Inc. PA increased its stake in shares of Lipocine by 9.2% in the second quarter. Federated Investors Inc. PA now owns 88,083 shares of the specialty pharmaceutical company’s stock valued at $354,000 after buying an additional 7,429 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Lipocine by 7.1% in the first quarter. Bank of New York Mellon Corp now owns 92,979 shares of the specialty pharmaceutical company’s stock valued at $362,000 after buying an additional 6,191 shares in the last quarter. 38.88% of the stock is currently owned by institutional investors.

About Lipocine

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.